Perdagangan Vir Biotechnology VIR

VirBiotechnology diagram langsung

Dasar-dasar Instrumen

Weekly Search
Weekly
Daily
Tanggal Tutup Ubah Ubah (%) Buka Tinggi Rendah

VirBiotechnology news

Berita Terkini

Tampilkan lebih banyak
Emma Rose 2025 Aug 15, 00:00

Fed Rate Cut Uncertainty Looms: Powell Navigates Rising Pressure

Liam James 2025 Aug 15, 00:00

Bitcoin and Ethereum Surge to New Highs Amidst Market Optimism

Sophia Claire 2025 Aug 15, 00:00

US Treasury Secretary Bessent Defends Fed Rate Cut Comments, Citing Model Suggestion

Noah Lee 2025 Aug 15, 00:00

Fundstrat Bullish on Ethereum: Growth Drivers and Price Predictions

Frances Wang 2025 Aug 14, 16:00

Stock market today: FTSE 100, DAX 30, CAC 40, Nikkei 225

Indices
Frances Wang 2025 Aug 14, 16:00

Shiba Inu Coin News: What’s Going on With Shiba Coin?

Cryptocurrencies
Liam James 2025 Aug 14, 00:00

US Interest Rate Cut Debate Heats Up: Will September See Action?

Emma Rose 2025 Aug 14, 00:00

Easing Sanctions on Russia: A Delicate Balance Between Ceasefire and European Interests

Info

Spread

0.03

Spread (%)

0.6637 %

Leverage

1:10

Bunga Overnight Beli

-0.0597 %

Bunga Overnight Jual

-0.0292 %

Mata Uang

USD

Jam Trading

Pasar tutup

Senin

13:31 - 19:59

Selasa

13:31-19:59

Rabu

13:31-19:59

Kamis

13:31-19:59

Jumat

13:31-19:59

Analisis dan Statistik

Buka

---

Sebelumnya Tutup

---

52 Minggu Tigg/Rdh

--- – ---

Kapitalisasi Pasar

616787072

Saham yang Beredar

138916000

Tanggal Penghasilan (Berikutnya)

0000-00-00

Hasil Div

Tanggal Non-Dividen

Proyeksi tingkat dividen tahunan

0

Proyeksi hasil dividen tahunan

0

EPS

-4.01

Pelajari lebih lanjut tentang instrumen ini

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

latest_education_articles

Tampilkan lebih banyak
Trustpilot